The FDA has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding the company’s syndromic ...
These pathogens are identified as primary causes of gastrointestinal illnesses by the Infectious Diseases Society of America. The panel “complements” the QIAstat-Dx Gastrointestinal Panel 2 ...
It is designed to complement the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (Bacterial & Viral) that covers Campylobacter, Salmonella, Shiga-like toxin-producing Escherichia coli (STEC ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has ...
The QIAstat-Dx Gastrointestinal Panel 2 Mini B is optimized for settings where bacterial pathogens are the primary concern, complementing the previously cleared QIAstat-Dx Gastrointestinal Panel 2 ...
QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...